PTC Therapeutics reported Q4 2025 total revenues of USD 164.7 million (-22.8%) and total net product revenues of USD 184.0 million, alongside a Q4 2025 net loss attributable to common stockholders of USD 135.0 million. For FY 2025, PTC posted total revenues of USD 1.73 billion (more than 2x) including collaboration and license revenue of USD 998.4 million tied to the votoplam license and collaboration agreement with Novartis that closed in January 2025. FY 2025 total net product revenues were USD 586.7 million, and net income attributable to common stockholders was USD 682.6 million. Cash, cash equivalents and marketable securities were USD 1.95 billion at December 31, 2025. By product, Q4 2025 Translarna net product revenues were USD 39.0 million (-56.2%) and Emflaza net product revenues were USD 27.1 million (-46.3%); FY 2025 Translarna net product revenues were USD 235.3 million (-26.7%) and Emflaza net product revenues were USD 146.4 million (-29.3%). Roche-reported Evrysdi FY 2025 sales were approximately CHF 1.76 billion, generating royalty revenue to PTC of USD 244.2 million in FY 2025 (+19.8%). PTC said its Sephience launch drove Q4 2025 revenue of USD 92.0 million (USD 81.0 million U.S.; USD 11.0 million ex-U.S.) and FY 2025 revenue of USD 111.0 million since launch, with 946 patients on commercial therapy worldwide as of December 31, 2025. Corporate updates included the December 2025 sale of the remainder of PTC’s Evrysdi royalty to Royalty Pharma for USD 240.0 million upfront plus up to USD 60.0 million in sales-based milestones, while retaining the right to receive a USD 150.0 million milestone from Roche based on single-year Evrysdi sales of USD 2.5 billion. PTC also said it held an end-of-Phase 2 meeting with the FDA in Q4 2025 for its votoplam Huntington’s disease program, with alignment on the design of the global Phase 3 INVEST-HD trial planned to start in 1H 2026, and noted an FDA Type C meeting in December 2025 for vatiquinone in Friedreich’s ataxia indicating an additional study would be needed for NDA resubmission. For FY 2026, PTC guided to total product revenue of USD 700.0 million to USD 800.0 million and GAAP R&D and SG&A expense of USD 775.0 million to USD 815.0 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191601PR_NEWS_USPR_____NY91828) on February 19, 2026, and is solely responsible for the information contained therein.